Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)

Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments. The 2027 Hospital Outpatient Prospective Payment System and ASC proposed rule are key catalysts for BVS's recent stock surge.

Bioventus Inc. ( BVS ) is an international medical technology firm that develops and sells products that support active healing and recovery. This includes products that aid in pain relief and recovery for the musculoskeletal system. Essentially, Bioventus provides both medical devices